World Pharma News Digest - 24.02.2014
7 views
Skip to first unread message
Ruslan David
Feb 24, 2014, 5:16:15 AM2/24/14
to worldph...@googlegroups.com
Nanoparticles target anti-inflammatory drugs where needed
Researchers at the University of Illinois at Chicago have developed a system for precisely delivering anti-inflammatory drugs to immune cells gone out of control, while sparing their well-behaved counterparts. Their findings were published online Feb. 23 in Nature Nanotechnology. The system uses nanoparticles made of tiny bits of protein designed to bind to unique receptors found only on neutrophils, a type of immune cell engaged in detrimental acute and chronic inflammatory responses.
Read more...
http://www.worldpharmanews.com/research/2711-nanoparticles-target-anti-inflammatory-drugs-where-needed
Eliquis® (apixaban) reduced the risk of stroke and demonstrated fewer major bleeding events versus Warfarin
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) have announced results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial in relation to patient age. ARISTOTLE was designed to evaluate the efficacy and safety of Eliquis compared to warfarin for reducing the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).
Read more...
http://www.worldpharmanews.com/pfizer/2710-eliquisr-apixaban-reduced-the-risk-of-stroke-and-demonstrated-fewer-major-bleeding-events-versus-warfarin
Scientists find resistance mechanism that could impact antibiotic drug development
The use of antibiotics is often considered among the most important advances in the treatment of human disease. Unfortunately, though, bacteria are finding ways to make a comeback. According to the Centers for Disease Control, more than two million people come down with antibiotic-resistant infections annually, and at least 23,000 die because their treatment can't stop the infection.
Read more...
http://www.worldpharmanews.com/research/2709-scientists-find-resistance-mechanism-that-could-impact-antibiotic-drug-development
Bevacizumab (Avastin) fails to improve survival for newly diagnosed glioblastoma patients
Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients newly diagnosed with the often deadly brain cancer glioblastoma, researchers report in the Feb. 20 issue of the New England Journal of Medicine.
Read more...
http://www.worldpharmanews.com/research/2708-bevacizumab-avastin-fails-to-improve-survival-for-newly-diagnosed-glioblastoma-patients
Boehringer Ingelheim receives East Bay Innovation Award
Boehringer Ingelheim Fremont Inc. received the East Bay Innovation Award in recognition for its contribution to the East Bay's culture of innovation. Boehringer Ingelheim's Fremont, California site is an arm of its biopharmaceutical division and provides the entire production technology chain from DNA to drug substance.
Read more...
http://www.worldpharmanews.com/boehringer-ingelheim/2707-boehringer-ingelheim-receives-east-bay-innovation-award
New drug candidate starves dormant cancer cells
In a study published in Nature Communications, researchers at Karolinska Institutet and Uppsala University in Sweden present a new drug candidate, which selectively kills dormant cells within a cancer tumour through starvation. These tumour cells, which are found in less oxygenated parts of solid tumours, are resistant to conventional treatments.
Read more...
http://www.worldpharmanews.com/research/2706-new-drug-candidate-starves-dormant-cancer-cells
Clinical trial success influenced by biomarker- and receptor-targeted therapies in NSCLC
Over the past decade, a great clinical focus has been directed at developing new and innovative therapies for advanced non-small cell lung cancer (NSCLC). An analysis of clinical trials evaluating these therapies demonstrates that the cumulative success rate for new agents for advanced NSCLC is lower than the industry-estimated rate. However, biomarker- and receptor-targeted therapies were found to substantially increase clinical trial success.
Read more...
http://www.worldpharmanews.com/research/2705-clinical-trial-success-influenced-by-biomarker-and-receptor-targeted-therapies-in-nsclc
Novartis expands cancer immunotherapy research program with acquisition of CoStim
Novartis announced today that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals Inc., a Cambridge, MA-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer.
Read more...
http://www.worldpharmanews.com/novartis/2704-novartis-expands-cancer-immunotherapy-research-program-with-acquisition-of-costim
PharmaNews.eu / Latest News
Scientists unlock a 'microbial Pompeii'
http://www.pharmanews.eu/research-and-development/1407-scientists-unlock-a-microbial-pompeii
eHealth Forum 2014
http://www.pharmanews.eu/conferences-and-events/1406-ehealth-forum-2014
Kidney cancer reveals its weak link
http://www.pharmanews.eu/research-and-development/1405-kidney-cancer-reveals-its-weak-link
New blood cells fight brain inflammation
http://www.pharmanews.eu/research-and-development/1404-new-blood-cells-fight-brain-inflammation
Two new weapons in the battle against bacteria
http://www.pharmanews.eu/research-and-development/1403-two-new-weapons-in-the-battle-against-bacteria
"Green light" for Bayer's new transparent low dose contraceptive patch
http://www.pharmanews.eu/bayer/1402-qgreen-lightq-for-bayers-new-transparent-low-dose-contraceptive-patch
mHealth Summit Europe 2014 Call for Papers
http://www.pharmanews.eu/conferences-and-events/1401-mhealth-summit-europe-2014-call-for-papers
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please download World Pharma News' Media Pack: http://www.worldpharmanews.com/contact-us
Researchers at the University of Illinois at Chicago have developed a system for precisely delivering anti-inflammatory drugs to immune cells gone out of control, while sparing their well-behaved counterparts. Their findings were published online Feb. 23 in Nature Nanotechnology. The system uses nanoparticles made of tiny bits of protein designed to bind to unique receptors found only on neutrophils, a type of immune cell engaged in detrimental acute and chronic inflammatory responses.
Read more...
http://www.worldpharmanews.com/research/2711-nanoparticles-target-anti-inflammatory-drugs-where-needed
Eliquis® (apixaban) reduced the risk of stroke and demonstrated fewer major bleeding events versus Warfarin
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) have announced results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial in relation to patient age. ARISTOTLE was designed to evaluate the efficacy and safety of Eliquis compared to warfarin for reducing the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).
Read more...
http://www.worldpharmanews.com/pfizer/2710-eliquisr-apixaban-reduced-the-risk-of-stroke-and-demonstrated-fewer-major-bleeding-events-versus-warfarin
Scientists find resistance mechanism that could impact antibiotic drug development
The use of antibiotics is often considered among the most important advances in the treatment of human disease. Unfortunately, though, bacteria are finding ways to make a comeback. According to the Centers for Disease Control, more than two million people come down with antibiotic-resistant infections annually, and at least 23,000 die because their treatment can't stop the infection.
Read more...
http://www.worldpharmanews.com/research/2709-scientists-find-resistance-mechanism-that-could-impact-antibiotic-drug-development
Bevacizumab (Avastin) fails to improve survival for newly diagnosed glioblastoma patients
Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients newly diagnosed with the often deadly brain cancer glioblastoma, researchers report in the Feb. 20 issue of the New England Journal of Medicine.
Read more...
http://www.worldpharmanews.com/research/2708-bevacizumab-avastin-fails-to-improve-survival-for-newly-diagnosed-glioblastoma-patients
Boehringer Ingelheim receives East Bay Innovation Award
Boehringer Ingelheim Fremont Inc. received the East Bay Innovation Award in recognition for its contribution to the East Bay's culture of innovation. Boehringer Ingelheim's Fremont, California site is an arm of its biopharmaceutical division and provides the entire production technology chain from DNA to drug substance.
Read more...
http://www.worldpharmanews.com/boehringer-ingelheim/2707-boehringer-ingelheim-receives-east-bay-innovation-award
New drug candidate starves dormant cancer cells
In a study published in Nature Communications, researchers at Karolinska Institutet and Uppsala University in Sweden present a new drug candidate, which selectively kills dormant cells within a cancer tumour through starvation. These tumour cells, which are found in less oxygenated parts of solid tumours, are resistant to conventional treatments.
Read more...
http://www.worldpharmanews.com/research/2706-new-drug-candidate-starves-dormant-cancer-cells
Clinical trial success influenced by biomarker- and receptor-targeted therapies in NSCLC
Over the past decade, a great clinical focus has been directed at developing new and innovative therapies for advanced non-small cell lung cancer (NSCLC). An analysis of clinical trials evaluating these therapies demonstrates that the cumulative success rate for new agents for advanced NSCLC is lower than the industry-estimated rate. However, biomarker- and receptor-targeted therapies were found to substantially increase clinical trial success.
Read more...
http://www.worldpharmanews.com/research/2705-clinical-trial-success-influenced-by-biomarker-and-receptor-targeted-therapies-in-nsclc
Novartis expands cancer immunotherapy research program with acquisition of CoStim
Novartis announced today that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals Inc., a Cambridge, MA-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer.
Read more...
http://www.worldpharmanews.com/novartis/2704-novartis-expands-cancer-immunotherapy-research-program-with-acquisition-of-costim
PharmaNews.eu / Latest News
Scientists unlock a 'microbial Pompeii'
http://www.pharmanews.eu/research-and-development/1407-scientists-unlock-a-microbial-pompeii
eHealth Forum 2014
http://www.pharmanews.eu/conferences-and-events/1406-ehealth-forum-2014
Kidney cancer reveals its weak link
http://www.pharmanews.eu/research-and-development/1405-kidney-cancer-reveals-its-weak-link
New blood cells fight brain inflammation
http://www.pharmanews.eu/research-and-development/1404-new-blood-cells-fight-brain-inflammation
Two new weapons in the battle against bacteria
http://www.pharmanews.eu/research-and-development/1403-two-new-weapons-in-the-battle-against-bacteria
"Green light" for Bayer's new transparent low dose contraceptive patch
http://www.pharmanews.eu/bayer/1402-qgreen-lightq-for-bayers-new-transparent-low-dose-contraceptive-patch
mHealth Summit Europe 2014 Call for Papers
http://www.pharmanews.eu/conferences-and-events/1401-mhealth-summit-europe-2014-call-for-papers
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please download World Pharma News' Media Pack: http://www.worldpharmanews.com/contact-us
Reply all
Reply to author
Forward
0 new messages